Splenic iron decreases without change in volume or liver parameters during luspatercept therapy

2.

Cappellini

MD

,

Viprakasit

V

,

Taher

AT

, et al.

A phase 3 trial of luspatercept in patients with transfusion-dependent beta-thalassemia

.

N Engl J Med

.

2020

;

382

(

13

):

1219

-

1231

.

3.

Angelucci

E

,

Brittenham

GM

,

McLaren

CE

, et al.

Hepatic iron concentration and total body iron stores in thalassemia major

.

N Engl J Med

.

2000

;

343

(

5

):

327

-

331

.

4.

Cappellini

MD

,

Taher

AT

.

The use of luspatercept for thalassemia in adults

.

Blood Adv

.

2021

;

5

(

1

):

326

-

333

.

5.

Taher

AT

,

Cappellini

MD

,

Kattamis

A

, et al.

Luspatercept for the treatment of anaemia in non-transfusion-dependent beta-thalassaemia (BEYOND): a phase 2, randomised, double-blind, multicentre, placebo-controlled trial

.

Lancet Haematol

.

2022

;

9

(

10

):

e733

-

e744

.

6.

Wood

JC

,

Enriquez

C

,

Ghugre

N

, et al.

MRI R2 and R2∗ mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patients

.

Blood

.

2005

;

106

(

4

):

1460

-

1465

.

7.

Ghugre

NR

,

Wood

JC

.

Relaxivity-iron calibration in hepatic iron overload: probing underlying biophysical mechanisms using a Monte Carlo model

.

Magn Reson Med

.

2011

;

65

(

3

):

837

-

847

.

8.

Brewer

CJ

,

Coates

TD

,

Wood

JC

.

Spleen R2 and R2∗ in iron-overloaded patients with sickle cell disease and thalassemia major

.

J Magn Reson Imaging

.

2009

;

29

(

2

):

357

-

364

.

9.

Nemeth

E

,

Ganz

T

.

The role of hepcidin in iron metabolism

.

Acta Haematol

.

2009

;

122

(

2-3

):

78

-

86

.

10.

Nemeth

E

.

Hepcidin in beta-thalassemia

.

Ann N Y Acad Sci

.

2010

;

1202

:

31

-

35

.

11.

Garbowski

MW

,

Ugidos

M

,

Risueno

A

, et al.

Luspatercept redistributes body iron to the liver in transfusion-dependent-thalassemia (TDT) during erythropoietic response

.

Blood

.

2021

;

138

(

suppl 1

):

761

.

12.

Rivella

S

.

Iron metabolism under conditions of ineffective erythropoiesis in beta-thalassemia

.

Blood

.

2019

;

133

(

1

):

51

-

58

.

13.

Crichton

RR

,

Ward

RJ

,

Hider

RC

.

The efficacy of iron chelators for removing iron from specific brain regions and the pituitary-ironing out the brain

.

Pharmaceuticals

.

2019

;

12

(

3

):

138

.

14.

Coates

TD

.

Physiology and pathophysiology of iron in hemoglobin-associated diseases

.

Free Radic Biol Med

.

2014

;

72

:

23

-

40

.

15.

Kubasch

AS

,

Fenaux

P

,

Platzbecker

U

.

Development of luspatercept to treat ineffective erythropoiesis

.

Blood Adv

.

2021

;

5

(

5

):

1565

-

1575

.

16.

Cazzola

M

.

Ineffective erythropoiesis and its treatment

.

Blood

.

2022

;

139

(

16

):

2460

-

2470

.